文献
J-GLOBAL ID:201802259501914670
整理番号:18A0385894
ランダム化治療中止と再治療を用いた中等度から重度の乾癬患者の治療のためのアダリムマブと比較した,抗インターロイキン23モノクローナル抗体,グセルクマブの有効性と安全性:第III相二重盲検プラセボと活性比較対照航海2試験の結果【Powered by NICT】
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial
著者 (10件):
Reich Kristian
(Dermatologikum Hamburg and SCIderm Research Institute, Hamburg, Germany)
,
Armstrong April W.
(University of Southern California, Los Angeles, California)
,
Foley Peter
(University of Melbourne, St Vincent’s Hospital, Melbourne, Australia)
,
Foley Peter
(Skin and Cancer Foundation Inc, Carlton, Australia)
,
Song Michael
(Janssen Research & Development, LLC, Spring House, Pennsylvania)
,
Wasfi Yasmine
(Janssen Research & Development, LLC, Spring House, Pennsylvania)
,
Randazzo Bruce
(Janssen Research & Development, LLC, Spring House, Pennsylvania)
,
Li Shu
(Janssen Research & Development, LLC, Spring House, Pennsylvania)
,
Shen Y.-K.
(Janssen Research & Development, LLC, Spring House, Pennsylvania)
,
Gordon Kenneth B.
(Northwestern University, Feinberg School of Medicine, Chicago, Illinois)
資料名:
Journal of the American Academy of Dermatology
(Journal of the American Academy of Dermatology)
巻:
76
号:
3
ページ:
418-431
発行年:
2017年
JST資料番号:
E0567B
ISSN:
0190-9622
資料種別:
逐次刊行物 (A)
記事区分:
原著論文
発行国:
オランダ (NLD)
言語:
英語 (EN)